MİDE ADENOKARSİNOMLARINDA PRİMER TÜMÖR VE KARACİĞER METASTAZLARININ FDG PET/BT PARAMETRELERİNİN KARŞILAŞTIRILMASI

Abstract

Mide kanserinde evreleme, yeniden evreleme ve tedaviye yanıt değerlendirme amacı ile [18F]-2-floro-2-deoksi-D-glukoz (FDG) pozitron emisyon tomografisi (PET)/bilgisayarlı tomografi (BT) görüntüleme yapılmaktadır. FDG PET/BT görüntülemede, primer tümörün ve metastazlarının metabolik parametreleri olan maksimum standart uptake değeri (SUVmaks) ve tümör lezyon glikolizi (TLG) değerlendirilmektedir. Bu retrospektif çalışmada evreleme amacı ile FDG PET/BT görüntülemeleri yapılan opere olmamış mide adenokarsinomlu hastalarda primer tümörün ve karaciğer metastazlarının metabolik parametrelerini elde etmeyi ve karşılaştırmayı amaçladık. Çalışmaya 11 erişkin olgu (altı kadın, beş erkek) dahil edildi. Primer mide tümörlerinin ve karaciğer metastazlarının (n=24) SUVmaks ve TLG değerleri elde edildi ve independent sample t-test yapılarak karşılaştırıldı. Primer mide tümörlerinin ve karaciğer metastazlarının ortalama SUVmaks değerleri sırasıyla 8.3±3.3 ve 7.6±1.8 olarak bulundu (P<0.05).  Primer mide tümörlerinin ve karaciğer metastazlarının ortalama TLG değerleri sırasıyla 84.7±60.2 ve 127.9±39.7 olarak bulundu (P<0.05). Primer mide tümörü ve karaciğer metastazlarının FDG PET/BT ile elde edilen metabolik parametreleri arasında anlamlı farklılık saptanmıştır. Karaciğer metastazlarına ait ortalama TLG değeri, primer tümörlerin ortalama TLG değerinden daha yüksek çıktığı için, bu olguların FDG PET/BT incelemesi yapılırken SUVmaks yanında TLG değerlerinin de dikkate alınmasının değerlendirmeye önemli katkı sağlayacağı düşünülmüştür. Primer mide malignitesinin ve karaciğer metastazlarının metabolik parametrelerini elde etmede FDG PET/BT etkin bir yöntemdir. 

Keywords

• Fluorodeoksiglukoz F18,pozitron-emisyon tomografi/bilgisayarlı tomografi,mide neoplazmları,neoplazm metastazları,karaciğer

COMPARISON OF THE FDG PET/CT PARAMETERS OF PRIMARY TUMORS AND LIVER METASTASES IN CASES WITH GASTRIC ADENOCARCINOMAS

Abstract

Abstract

[18F]-2-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET)/ computed tomography (CT) imaging is being performed for staging, restaging and evaluation of response to treatment in gastric cancer. In FDG PET/CT imaging, metabolic parameters of the primary tumors and their metastases, namely the maximum standard uptake value (SUVmax) and the tumor lesion glycolysis (TLG) are evaluated. In this retrospective study, we aimed to obtain and compare the metabolic parameters of the primary tumors and their liver metastases in patients with gastric cancer who underwent FDG PET/CT imaging and who didn’t undergo surgery. Eleven patients (six females, five males) were included in the study. SUVmax and ve TLG values of the primary tumors and their liver metastases (n=24) were obtained and compared using independent sample t-test. The mean SUVmax of the primary gastric tumors and their liver metastases were 8.3±3.3 ve 7.6±1.8, respectively (P<0.05). The mean TLG of the primary gastric tumors and their liver metastases were 84.7±60.2 ve 127.9±39.7, respectively (P<0.05). There were significant differences between metabolic parameters of the primary tumors and their liver metastases. Since the mean TLG value of the liver metastases were higher than that of the primary tumor, taking TLG values into account beside SUVmax values were considered to make significant contribution to FDG PET/CT evaluation of these cases. FDG PET/CT is an effective tool in obtaining metabolic parameters of primary gastric malignancies and their liver metastases. 

Keywords

• Fluorodeoxyglucose F18,positron-emission tomography/computed tomography,stomach neoplasms,neoplasm metastasis,liver

References

1. 1. Hopkins S, Yang GY. (2011). FDG PET imaging in the staging and management of gastric cancer. J Gastrointest Oncol; 2(1):39–44.
2. 2. Lim JS, Yun MJ, Kim MJ, Hyung WJ, Park MS, Choi JY, Kim TS, Lee JD, Noh SH, Kim KW. (2006). CT and PET in stomach cancer: preoperative staging and monitoring of response to therapy. Radiographics; 26(1):14–56.
3. 3. Alobthani G, Romanov V, Isohashi K, Matsunaga K, Watabe T, Kato H, Tatsumi M, Shimosegawa E, Hatazawa J. (2018). Value of 18F-FDG PET/CT in discrimination between indolent and aggressive non-Hodgkin's lymphoma: A study of 328 patients. Hell J Nucl Med; 21(1):7−14.
4. 4. Singh D, Miles K. (2012). Multiparametric PET/CT in oncology. Cancer Imaging; 12:336−44.
5. 5. d'Amico A. (2015). Review of clinical practice utility of positron emission tomography with 18F-fluorodeoxyglucose in assessing tumour response to therapy. Radiol Med; 120(4):345−51.
6. 6. Satoh Y, Nambu A, Ichikawa T, Onishi H. (2014). Whole-body total lesion glycolysis measured on fluorodeoxyglucose positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer. BMC Cancer; 14:525.
7. 7. Altini C, Niccoli Asabella A, Di Palo A, Fanelli M, Ferrari C, Moschetta M, Rubini G. (2015). 18F-FDG PET/CT role in staging of gastric carcinomas: comparison with conventional contrast enhancement computed tomography. Medicine (Baltimore); 94(20):e864.
8. 8. Soret M, Bacharach SL, Buvat I. (2007). Partial-volume effect in PET tumor imaging. J Nucl Med; 48(6):932−45.

9. 9. Lee SY, Seo HJ, Kim S, Eo JS, Oh SC. (2018). Prognostic significance of interim 18 F-fluorodeoxyglucose positron emission tomography-computed tomography volumetric parameters in metastatic or recurrent gastric cancer. Asia Pac J Clin Onco; 14(5):e302-e309.
10. 10. Lim SM, Kim H, Kang B, Kim HS, Rha SY, Noh SH, Hyung WJ, Cheong JH, Kim HI, Chung HC, Yun M, Cho A, Jung M. (2016). Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography in patients with gastric neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma. Ann Nucl Med; 30(4):279–86.
11. 11. Woff E, Hendlisz A, Ameye L, Garcia C, Kamoun T, Guiot T, Paesmans M, Flamen P. (2018). Validation of metabolically active tumor volume and total lesion glycolysis as 18F-FDGPET/CT–derived prognostic biomarkers in chemorefractory metastatic colorectal cancer. J Nucl Med; doi: 10.2967/jnumed.118.210161. [Epub ahead of print]
12. 12. Grut H, Dueland S, Line PD, Revheim ME. (2018). The prognostic value of 18F-FDG PET/CT prior to liver transplantation for nonresectable colorectal liver metastases. Eur J Nucl Med Mol Imaging; 45(2):218−25.